These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37314825)

  • 21. Ignoring the Experts: Implications of the FDA's Aduhelm Approval.
    Maulden A
    Am J Law Med; 2022 Mar; 48(1):108-133. PubMed ID: 35815585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CMS Proposes Medicare Coverage Policy for Monoclonal Antibody-Based Alzheimer Treatment.
    J Nucl Med; 2022 Mar; 63(3):12N. PubMed ID: 35232884
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA Approval of Aduhelm Paves a New Path for Alzheimer's Disease.
    Tanzi RE
    ACS Chem Neurosci; 2021 Aug; 12(15):2714-2715. PubMed ID: 34259498
    [No Abstract]   [Full Text] [Related]  

  • 24. Update: FDA approval of Biogen's aducanumab.
    Hollmann P
    Geriatr Nurs; 2022; 43():318-319. PubMed ID: 34996638
    [No Abstract]   [Full Text] [Related]  

  • 25. Does the FDA-approved Alzheimer drug aducanumab have a place in the Australian pharmacopoeia?
    Gleason A; Ayton S; Bush AI
    Med J Aust; 2022 Mar; 216(4):172-174. PubMed ID: 35141902
    [No Abstract]   [Full Text] [Related]  

  • 26. Controversial Approval of New Drug to Treat Alzheimer's Disease.
    Aschenbrenner DS
    Am J Nurs; 2021 Oct; 121(10):22-23. PubMed ID: 34554982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA approves galantamine for Alzheimer's disease.
    Thompson CA
    Am J Health Syst Pharm; 2001 Apr; 58(8):649. PubMed ID: 11329755
    [No Abstract]   [Full Text] [Related]  

  • 28. Alzheimer's and Aducanumab: Unjust Profits and False Hopes.
    Fleck LM
    Hastings Cent Rep; 2021 Jul; 51(4):9-11. PubMed ID: 34156732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From proposal to patient: how CMS makes coverage decisions.
    Turnbull GB
    Ostomy Wound Manage; 2002 Apr; 48(4):8-10, 82. PubMed ID: 11993063
    [No Abstract]   [Full Text] [Related]  

  • 30. Using the MADIT II criteria for implantable cardioverter defibrillators-what is the role of the Food and Drug Administration approval?
    Barold HS
    Card Electrophysiol Rev; 2003 Dec; 7(4):443-6. PubMed ID: 15071272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's drug approval gets a mixed reception.
    Couzin-Frankel J
    Science; 2023 Jan; 379(6628):126-127. PubMed ID: 36634171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 33. Aduhelm: The Best Hope for Alzheimer's Disease Patients or the Worst Decision the FDA Has Ever Made?
    Kurkinen M; Tran L
    J Alzheimers Dis; 2021; 84(3):969-971. PubMed ID: 34657888
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA is criticised for licensing high dose donepezil.
    Lenzer J
    BMJ; 2011 May; 342():d3270. PubMed ID: 21613347
    [No Abstract]   [Full Text] [Related]  

  • 35. Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain.
    Chambers JD; May KE; Neumann PJ
    Health Aff (Millwood); 2013 Jun; 32(6):1109-15. PubMed ID: 23733986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Include Payers in Your Product Development and Clinical Use Processes.
    Schaum KD
    Adv Wound Care (New Rochelle); 2020 Nov; 9(11):632-635. PubMed ID: 32311305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aduhelm, the Newly Approved Medication for Alzheimer Disease: What Epidemiologists Can Learn and What Epidemiology Can Offer.
    Glymour MM; Weuve J; Dufouil C; Mayeda ER
    Am J Epidemiol; 2022 Jul; 191(8):1347-1351. PubMed ID: 35388413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
    Zissimopoulos J; Jacobson M; Chen Y; Borson S
    JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Medicare Coverage of Aducanumab - Implications for State Budgets.
    Sachs RE; Bagley N
    N Engl J Med; 2021 Nov; 385(22):2019-2021. PubMed ID: 34797617
    [No Abstract]   [Full Text] [Related]  

  • 40. What the Aducanumab Approval Reveals About Alzheimer Disease Research.
    Manly JJ; Glymour MM
    JAMA Neurol; 2021 Nov; 78(11):1305-1306. PubMed ID: 34605885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.